(19)
(11) EP 1 028 947 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.01.2004 Bulletin 2004/05

(45) Mention of the grant of the patent:
12.06.2002 Bulletin 2002/24

(21) Application number: 98956442.2

(22) Date of filing: 05.11.1998
(51) International Patent Classification (IPC)7: C07D 233/64, A61K 31/415
(86) International application number:
PCT/US1998/023223
(87) International publication number:
WO 1999/024405 (20.05.1999 Gazette 1999/20)

(54)

H3 RECEPTOR LIGANDS OF THE PHENYL-ALKYL-IMIDAZOLES TYPE

PHENYLALKYL IMIDAZOLE DERIVATE ALS H3 REZEPTOR LIGANDEN

LIGANDS DU RECEPTEUR H3 DU TYPE PHENYL-ALKYL-IMIDAZOLE

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
Designated Extension States:
LT LV RO

(30) Priority: 07.11.1997 US 966344
05.08.1998 US 129711

(43) Date of publication of application:
23.08.2000 Bulletin 2000/34

(73) Proprietor: SCHERING CORPORATION
Kenilworth, New Jersey 07033-0530 (US)

(72) Inventor:
  • ASLANIAN, Robert, G.
    Rockaway, NJ 07866 (US)

(74) Representative: Ritter, Stephen David et al
Mathys & Squire 100 Gray's Inn Road
London WC1X 8AL
London WC1X 8AL (GB)


(56) References cited: : 
WO-A-93/14070
WO-A-96/29315
 WO-A-95/14007
WO-A-98/06394
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).